Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
melphalan + bortezomib + thalidomide + dexamethasone + cisplatin + doxorubicin + cyclophosphamide + etoposide
- Development stage
- Unknown
- Lead developer
- University of Arkansas for Medical Sciences
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
M-VTD-PACE is an intensive multi-agent combination chemotherapy regimen developed by the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (UAMS). It is primarily used in the context of the Total Therapy (TT) clinical trial program for multiple myeloma, specifically within the Standard Total Therapy 3 (S-TT3) arm of the TT4B trial for low-risk patients. The regimen is an expansion of the VTD-PACE backbone, which consists of bortezomib (V), thalidomide (T), dexamethasone (D), cisplatin (P), doxorubicin (A), cyclophosphamide (C), and etoposide (E). The 'M' prefix signifies the addition of the alkylating agent melphalan. This combination therapy targets multiple myeloma through diverse mechanisms, including proteasome inhibition, immunomodulation, DNA alkylation, and topoisomerase II inhibition, aiming to overcome drug resistance and improve therapeutic outcomes in newly diagnosed patients.
- Brand names
- Velcade (for bortezomib)Adriamycin (for doxorubicin)Platinol (for cisplatin)
- Other names
- M-VTD-PACEStandard Total Therapy 3S-TT3S-TT-3S-TT 3
02
Targets
TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)CRBN (Cereblon)PSMB5 (Proteasome subunit beta Type-5)DNA
Beyond the preview
Go deeper on melphalan + bortezomib + thalidomide + dexamethasone + cisplatin + doxorubicin + cyclophosphamide + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on melphalan + bortezomib + thalidomide + dexamethasone + cisplatin + doxorubicin + cyclophosphamide + etoposide.